Recent submissions

Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI

Coll, Llucia; Carbonell Mirabent, Pere; Castillo Justribo, Joaquin; Galan, Ingrid; Nos, Carlos; Auger, Cristina; Alberich, Manel; Pareto, Deborah; Cobo-Calvo, Alvaro; Vidal-Jordana, Angela; Comabella Lopez, Manuel; Rodriguez Acevedo, Breogan; Zabalza, Ana; midaglia, luciana; Rio, Jordi; Sastre Garriga, Jaume; Rovira, Alex; Tintore, Mar; TUR, CARMEN; Arrambide, Georgina; Montalban, Xavier (Publication date: 2024-06-11)

Deep learning; Multiple sclerosis; Structural MRI

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Coles, Alasdair; Traboulsee, Anthony; Singer, Barry A; Pozzilli, Carlo; Oreja-Guevara, C.; Achiron, Anat; Montalban, Xavier (Publication date: 2023-09-29)

Alemtuzumab; Disease-modifying therapy; Multiple sclerosis

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease

Mulero, Patricia; Rubio-Flores, Laura; Villacieros-Álvarez, Javier; Espejo, Carmen; Dinoto, Alessandro; Rovira, Alex; Auger, Cristina; Tintore, Mar; Cobo-Calvo, Alvaro; Arrambide, Georgina; Montalban, Xavier (Publication date: 2025-03-20)

Serum Cytokines; Prognosis; Myelin oligodendrocyte glycoprotein

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique

Tur Gomez, Carmen; De Angelis, Floriana; Prados, Ferran; Grussu, Francesco; Calvi, Alberto; Eshaghi, Arman; Kanber, Baris (Publication date: 2023-01-24)

Anisotropy; Lesion spatial distribution; Multiple sclerosis

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Kappos, Ludwig; Li, David K B; Bar-Or, Amit; Barkhof, Frederik; Traboulsee, Anthony; Montalban, Xavier (Publication date: 2024-02-01)

Disease-modifying therapies; Multiple sclerosis; Ocrelizumab

Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons

Pinteac, Rucsanda; Soriano Fradera, Jordi; Matute Blanch, Clara; lizcano, jose m; López Comellas, Gloria; Duarri, Anna; Malhotra Sareen, Sunny; Eixarch, Herena; Comabella Lopez, Manuel; Montalban, Xavier (Publication date: 2025-02-05)

Quitinasa; Esclerosis múltiple; Efectos neurotóxicos

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

Schmierer, Klaus; Wiendl, Heinz; Barkhof, Frederik; Achiron, Anat; Derfuss, Tobias; Montalban, Xavier (Publication date: 2025-10-14)

Cladribine; Immunoglobulins; Kappa free light chain

Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial

Arnold, Douglas; Elliott, Colm; Martin, Emily C.; Hyvert, Yann; Tomic, Davorka Lucia; Montalban, Xavier (Publication date: 2024-02-20)

Evobrutinib; Lesion; Relapsing multiple sclerosis

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement

Arrambide Garcia, Georgina; Kaplan, Batia; Khalil, Michael; Saadeh, Ruba; Hegen, Harald; Gnanapavan, Sharmilee (Publication date: 2023-04-17)

Líquido cefalorraquídeo; Consenso; Esclerosis múltiple

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program

Selmaj, Krzysztof W.; Cohen, Jeffrey A; Comi, Giancarlo; Arnold, Douglas L; Steinman, Lawrence; Montalban Gairín, Xavier; Bar-Or, Amit (Publication date: 2022-02-24)

Esdeveniments adversos; Esclerosi múltiple; Ozanimod

COVID-19 and multiple sclerosis: challenges and lessons for patient care

Prosperini, Luca; Celius, Elisabeth Gulowsen; Goletti, Delia; Killestein, Joep; Kos, Daphne; Arrambide, Georgina (Publication date: 2025-02-14)

COVID-19; Multiple sclerosis; SARS-CoV-2

Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis

Shatila, Madiha; Strijbis, Eva M.M.; Schoof, Lisa; Bollo, Luca; Brownlee, Wallace; Vidal-Jordana, Angela; Killestein, Joep; Rovira, Alex; Sastre Garriga, Jaume; Tintore, Mar; Montalban, Xavier (Publication date: 2025-03-10)

Diagnostic; Multiple sclerosis

IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis

Dema Etxezarreta, María; Eixarch, Herena; Castillo Juárez, Mireia; Espejo, Carmen; Montalban, Xavier (Publication date: 2024-07-04)

Ageing; Immunosenescence; Multiple sclerosis

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community

Thompson, Alan; Moccia, Marcello; Calabresi, Peter; Finlayson, Marcia; Hawton, Annemarie; amato, Maria Pia; Montalban, Xavier (Publication date: 2023-10-18)

Multiple sclerosis; Clinical course; Progression

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis

Resina Sallés, Mireia; Forner Puntonet, Mireia; Wu, Yanzhen; Rodriguez Acevedo, Breogan; Nos, Carlos; Montalban, Xavier (Publication date: 2025-01-08)

Alemtuzumab; Linfocitos; Esclerosis múltiple progresiva

A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

Boyko, Alexey; Correale, Jorge; Edan, Gilles; Freedman, Mark S; Giovannoni, Gavin; Montalban, Xavier (Publication date: 2023-12-19)

Cladribina; Multiple sclerosis; Relapses

Articles científics - CEMCAT: Recent submissions

Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI ﻿

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study ﻿

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease ﻿

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique ﻿

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension ﻿

Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons ﻿

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study ﻿

Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial ﻿

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement ﻿

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program ﻿

COVID-19 and multiple sclerosis: challenges and lessons for patient care ﻿

Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis ﻿

IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis ﻿

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community ﻿

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis ﻿

A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study ﻿